Given a high-density lipoprotein cholesterol of 2.1 mmol/L, total cholesterol of 6.2 mmol/L, and low-density lipoprotein cholesterol of 3.6 mmol/L, does the patient require lipid‑lowering therapy?

Does This Patient Need Lipid-Lowering Therapy?

The decision to initiate lipid-lowering therapy depends entirely on the patient's cardiovascular risk category, not on the lipid values alone. With an LDL-C of 3.6 mmol/L, this patient will require treatment if they are at high or very high cardiovascular risk, but may not need therapy if they are at low or moderate risk 1.

Risk-Based Treatment Algorithm

Step 1: Determine Cardiovascular Risk Category

The patient's need for therapy is determined by their risk stratification 1:

Very High Risk includes patients with:

• Established atherosclerotic cardiovascular disease (prior MI, ACS, stroke, PAD, carotid disease) 1
• Diabetes with target organ damage or multiple risk factors 1
• Chronic kidney disease stage 3-5 1
• Familial hypercholesterolemia with atherosclerotic disease 1

High Risk includes patients with:

• Markedly elevated single risk factors (e.g., LDL-C >4.9 mmol/L or 190 mg/dL) 1
• Diabetes without target organ damage but age >40 years with additional risk factors 1
• 10-year cardiovascular risk ≥10% by risk calculator 1

Step 2: Apply Treatment Goals Based on Risk

For Very High Risk Patients:

• LDL-C goal: <1.8 mmol/L (70 mg/dL) 1
• With baseline LDL-C of 3.6 mmol/L, this patient requires at least 50% reduction 1
• Lipid-lowering therapy is mandatory - initiate high-intensity statin immediately 1

For High Risk Patients:

• LDL-C goal: <2.6 mmol/L (100 mg/dL) 1
• With baseline LDL-C of 3.6 mmol/L, this patient requires at least 50% reduction 1
• Lipid-lowering therapy is indicated - initiate statin therapy 1

For Moderate/Low Risk Patients:

• With LDL-C of 3.6 mmol/L, lifestyle modifications may be sufficient initially 1
• However, the total cholesterol of 6.2 mmol/L is elevated and warrants attention 1

Key Clinical Considerations

The HDL-C Level is Protective

• The HDL-C of 2.1 mmol/L is actually favorable and protective 1
• This high HDL-C does not negate the need for LDL-C lowering in high-risk patients 1
• HDL-C is an independent risk factor but does not change LDL-C treatment targets 1

Screen for Familial Hypercholesterolemia

• LDL-C >5 mmol/L (190 mg/dL) in adults suggests possible familial hypercholesterolemia 1
• While this patient's LDL-C of 3.6 mmol/L is below this threshold, consider family history of premature CVD or tendon xanthomas 1
• If FH is suspected, intensive statin therapy (often with ezetimibe) is recommended regardless of risk score 1

Calculate Non-HDL-C as Secondary Target

• Non-HDL-C = Total cholesterol - HDL-C = 6.2 - 2.1 = 4.1 mmol/L 1
• For very high risk: non-HDL-C goal <2.6 mmol/L 1
• For high risk: non-HDL-C goal <3.4 mmol/L 1
• This patient's non-HDL-C of 4.1 mmol/L exceeds both targets 1

Common Pitfalls to Avoid

Do not be falsely reassured by the high HDL-C - while protective, it does not eliminate the need for LDL-C lowering in high-risk patients 1. The "lower is better" paradigm for LDL-C applies regardless of HDL-C levels 2.

Do not delay treatment in very high-risk patients - if this patient has established ASCVD, diabetes with complications, or CKD stage 3-5, high-intensity statin therapy should be initiated immediately without waiting for lifestyle modifications 1.

Recognize that most high-risk patients will need combination therapy - with an LDL-C of 3.6 mmol/L and a goal of <1.8 mmol/L (50% reduction), statin monotherapy may be insufficient 3, 2. Consider adding ezetimibe or PCSK9 inhibitors if goals are not met 2, 4.

Real-World Implementation Gap

Evidence shows that 75% of patients with established ASCVD have LDL-C above guideline targets, and over 50% are not treated with appropriate therapy 1. This represents a critical quality gap in cardiovascular care 1. Do not contribute to this undertreatment pattern if your patient qualifies for therapy based on risk stratification 1.